Effect of Levosimendan on Estimated Glomerular Filtration Rate in Hospitalized Patients with Decompensated Heart Failure and Renal Dysfunction

Cardiovascular Therapeutics

Volumn 31, Issue 2, 2013, Pages 108-114

  Hou, Zhi Qiang ^a   Sun, Zhao Xia ^b   Su, Chong Yi ^a   Tan, Hui ^a   Zhong, Xia ^a   Hu, Bo ^a   Zhou, Yi ^a   Shang, De Ya ^a  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^b Jinan 2nd People's Hospital   (China)

Author keywords

B type Natriuretic peptide; Decompensated heart failure; Estimated glomerular filtration rate; Levosimendan; Placebo; Renal dysfunction

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; LEVOSIMENDAN; PLACEBO;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE; HOSPITAL PATIENT; HUMAN; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; URINE VOLUME;

AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; BLOOD PRESSURE; CARDIOTONIC AGENTS; CHI-SQUARE DISTRIBUTION; CHINA; DOUBLE-BLIND METHOD; FEMALE; GLOMERULAR FILTRATION RATE; HEART FAILURE; HEART RATE; HOSPITALIZATION; HUMANS; HYDRAZONES; INFUSIONS, INTRAVENOUS; KIDNEY DISEASES; LINEAR MODELS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PROSPECTIVE STUDIES; PYRIDAZINES; STROKE VOLUME; TIME FACTORS; TREATMENT OUTCOME; URINATION; VENTRICULAR FUNCTION, LEFT;

EID: 84875767706     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/1755-5922.12001     Document Type: Article

References (29)

1. Brandimarte F, Vaduganathan M, Mureddu GF, et al. Prognostic implications of renal dysfunction in patients hospitalized with heart failure: Data from the last decade of clinical investigations. Heart Fail Rev 2012. doi/10.1007/s10741-012-9317-z..
2. Aronson D, Burger AJ. The relationship between transient and persistent worsening renal function and mortality in patients with acute decompensated heart failure. J Card Fail 2010;16: 541-547.
3. Tang WH, Mullens W. Cardiorenal syndrome in decompensated heart failure. Heart 2010;96: 255-260.
4. House AA, Haapio M, Lassus J, Ronco C. Pharmacological management of cardiorenal syndromes. Int J Nephrol 2011;2011: 630809.
5. Parissis JT, Rafouli-Stergiou P, Paraskevaidis I, Mebazaa A. Levosimendan: From basic science to clinical practice. Heart Fail Rev 2009;14: 265-275.
6. Fotbolcu H, Duman D. A promising new inotrope: Levosimendan. Anadolu Kardiyol Derg 2010;10: 176-182.
7. Follath F, Cleland JG, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): A randomised double-blind trial. Lancet 2002;360: 196-202.
8. Cleland JG, Freemantle N, Coletta AP, Clark AL. Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE. Eur J Heart Fail 2006;8: 105-110.
9. Mebazaa A, Nieminen MS, Packer M, et al. Levosimendan vs Dobutamine for patients with Acute Decompensated Heart Failure. The SURVIVE Randomized Trial. JAMA 2007;297: 1883-1891.
10. Packer M and the REVIVE II Trial Investigators. REVIVE II: Multicenter placebo-controlled trial of levosimendan on clinical status in acutely decompensated heart failure. Circulation 2005;112: 3363.
11. Yilmaz MB, Yalta K, Yontar C, et al. Levosimendan improves renal function in patients with acute decompensated heart failure: Comparison with dobutamine. Cardiovasc Drugs Ther 2007;21: 431-435.
12. Zemljic G, Bunc M, Yazdanbakhsh AP, Vrtovec B. Levosimendan improves renal function in patients with advanced chronic heart failure awaiting cardiac transplantation. J Card Fail 2007;13: 417-421.
13. Silva-Cardoso J, Ferreira J, Oliveira-Soares A, et al. Effectiveness and safety of levosimendan in clinical practice. Rev Port Cardiol 2009;28: 143-154.
14. Miller WG. Reporting estimated GFR: A laboratory perspective. Am J Kidney Dis 2008;52: 645-648.
15. Macisaac RJ, Tsalamandris C, Thomas MC, et al. Estimating glomerular filtration rate in diabetes: A comparison of cystatin-C- and creatinine-based methods. Diabetologia 2006;49: 1686-1689.
16. Pei XH, He J, Liu Q, et al. Evaluation of serum creatinine- and cystatin C-based equations for the estimation of glomerular filtration rate in a Chinese population. Scand J Urol Nephrol 2012;46: 223-231.
17. Lilleberg J, Laine M, Palkama T, Kivikko M, Pohjanjousi P, Kupari M. Duration of the haemodynamic action of a 24-h infusion of levosimendan in patients with congestive heart failure. Eur J Heart Fail 2007;9: 75-82.
18. Banfor PN, Preusser LC, Campbell TJ, et al. Comparative effects of levosimendan, OR-1896, OR-1855, dobutamine, and milrinone on vascular resistance, indexes of cardiac function, and O2 consumption in dogs. Am J Physiol Heart Circ Physiol 2008;294: H238-H248.
19. Tavares M, Andrade AC, Mebazaa A. Levosimendan use in several scenarios of acute heart failure. Arq Bras Cardiol 2008;90: 211-215.
20. Puttonen J, Kantele S, Kivikko M, Häkkinen S, Harjola VP, Koskinen P, Pentikäinen PJ. Effect of severe renal failure and haemodialysis on the pharmacokinetics of levosimendan and its metabolites. Clin Pharmacokinet 2007;46: 235-246.
21. McLean AS, Huang SJ, Nalos M, Ting I. Duration of the beneficial effects of levosimendan in decompensated heart failure as measured by echocardiographic indices and B-type natriuretic peptide. J Cardiovasc Pharmacol 2005;46: 830-835.
22. Feola M, Lombardo E, Taglieri C, Vallauri P, Piccolo S, Valle R. Effects of levosimendan/furosemide infusion on plasma brain natriuretic peptide, echocardiographic parameters and cardiac output in end-stage heart failure patients. Med Sci Monit 2011;17: PI7-PI13.
23. Yildiz O. Vasodilating mechanisms of levosimendan: Involvement of K+ channels. J Pharmacol Sci 2007;104: 1-5.
24. Damman K, Voors AA. Levosimendan improves renal function in acute decompensated heart failure: Cause and clinical application. Editorial to: "Levosimendan improves renal function in patients with acute decompensated heart failure: Comparison with dobutamine by Yilmaz et al." Cardiovasc Drugs Ther 2007;21: 403-404.
25. Ribeiro RA, Rohde LE, Polanczyk CA. Levosimendan in acute decompensated heart failure: Systematic review and meta-analysis. Arq Bras Cardiol 2010;95: 230-237.
26. Zager RA, Johnson AC, Lund S, Hanson SY, Abrass CK. Levosimendan protects against experimental endotoxemic acute renal failure. Am J Physiol Renal Physiol 2006;290: F1453-F1462.
27. Parissis JT, Farmakis D, Kremastinos DT. Anti-inflammatory effects of levosimendan in decompensated heart failure: Impact on weight loss and anemia. Am J Cardiol 2005;95: 923-924.
28. Yakut N, Yasa H, Bahriye Lafci B, et al. The influence of levosimendan and iloprost on renal ischemia-reperfusion: An experimental study. Interact Cardiovasc Thorac Surg 2008;7: 235-239.
29. Logeart D, Tabet JY, Hittinger L, et al. Transient worsening of renal function during hospitalization for acute heart failure alters outcome. Int J Cardiol 2008;127: 228-232.